Biohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk

Dow Jones

2025/12/27

11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com)

(END) Dow Jones Newswires

December 26, 2025 11:47 ET (16:47 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2594297111"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594297111\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594297111?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-27 00:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594297111","market":"nz","top_or_hot":-1,"title":"Biohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2025 11:47 ET (16:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-27 00:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2025 11:47 ET (16:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2594297111","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594297111","pubTimestamp":1766767620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"Biohaven的癫痫机会超过了抑郁症试验——市场讨论","themeId":"d018407bd33f27ba9ab8988ad29e6a0c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  December 26, 2025 11:47 ET (16:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}